Latest news from Datamonitor
pharmafile | May 28, 2008 | News story | Sales and Marketing |Â Â em, hcÂ
Potential lung cancer epidemic looming in Asia
Lung cancer is the leading cause of cancer-related mortality throughout much of the industrialized and developing world. Smoking is the main cause of lung cancer, but with smoking declining in most Western societies, it seems that the peak of the lung cancer incidence in the West has passed. In Asia, however, a lung cancer epidemic is looming, as more smokers die and more children take up smoking.
Lung cancer is still responsible for more deaths annually in Western countries than breast, colorectal and prostate cancers combined. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80% of all cases, and despite recent advances in treatment, NSCLC remains a disease of poor prognosis, with few treatment options available and an overall five-year survival rate of about 15%.
According to a new Datamonitor report, despite extensive R&D in the field, new drugs may struggle to improve NSCLC patient outcomes. However, research in the field of biomarkers may help to improve the treatment of the disease, tailoring therapy to individual patient characteristics.
In 2008, an estimated 360,000 people in the seven major markets of the UK, Japan, France, Germany, Italy, Spain and the US will be diagnosed with NSCLC. Currently, screening programs are not part of standard clinical practice to routinely detect early development of the disease. As NSCLC is often asymptomatic until it has progressed, the majority of patients will be diagnosed with the advanced stage of the disease where treatment has a palliative, rather than curative intent.
The primary risk factor for NSCLC is smoking, which is responsible for more than 85% of all lung cancer-related deaths. The risk for lung cancer increases with the number of cigarettes smoked per day and the number of years spent smoking.
Although the peak of the lung cancer epidemic seems to have passed in the US, Western and northern Europe, Asia is expected to face a major epidemic in the future, according to analysts, as smoking is increasing in this region.
Despite recent advances and the increased role of molecular targeted therapies in treatment, NSCLC remains a disease of poor prognosis, with few treatment options available for patients with advanced disease. Surgery can be curative in earlier stages of the disease but patients' older age, associated co-morbidities or advanced disease stage often prohibit its use. As a result, it is estimated that only about 20% of all patients are considered surgical candidates at presentation. Moreover, more than half of patients die of tumor progression after complete surgical resection.
In the management of advanced disease, which is largely based on conventional chemotherapy, the role of molecular targeted therapies is still limited. Genentech/Roche's Avastin is the only targeted therapy to receive approval for the first-line treatment of advanced disease, extending patient median survival when used in combination with chemotherapy. However, due to safety concerns, not all patients are eligible for treatment with Avastin. Similarly, other targeted therapies such as Tarceva (OSI Pharmaceuticals/Genentech//Roche/Chugai) and Iressa (AstraZeneca) seem to be more effective only in certain patient populations, thus limiting the number of patients who can truly benefit from treatment.
The high level of unmet need in the treatment of the disease and the large patient population are, however, driving extensive R&D activity in the field of NSCLC. Currently, there are over 100 drugs in development, more than half of which are molecular targeted therapies.
Many researchers are of the opinion that an efficacy plateau has been reached with conventional chemotherapy in the treatment of NSCLC. Therefore, most drug developers are investing their resources in the development of novel molecular targeted therapies, in an attempt to improve on the activity and toxicity of chemotherapy. Molecular targeted therapies are the focus of development, accounting for 60% of the entire NSCLC pipeline.
Due to the clinical and molecular heterogeneity of NSCLC, improvements in patient outcomes are likely to arise from targeting multiple signaling pathways, including angiogenesis and apoptosis.
It is becoming increasingly clear that NSCLC is a highly heterogeneous disease. This leads to variations in the response to treatment, with survival and sensitivity often being restricted to subgroups of patients. Unfortunately, increasing evidence suggests that new drugs may struggle to improve patient outcomes in unselected patient populations.
In order to maximize the therapeutic potential of novel drugs, developers are currently investigating the field of biomarkers. Biomarkers, when positive, are thought to be predictive for response to treatment, although their correlation with prognosis and survival is less well-defined. Analysts contend that their use can help in the selection of patients who have more chances of responding to a particular therapy. Biomarkers may also allow, for example, for the selection of patients who are most likely to recur after surgery and should therefore require post-operative therapy. Many analysts believe that this type of individualized medicine – tailoring therapy to patients' clinical or molecular characteristics – may help to improve survival for NSCLC patients in the future.
Related research:
Pipeline Insight: Non-Small Cell Lung Cancer – Pipeline set to offer only modest improvements
Pipeline Insight: Molecular Targeted Cancer Therapies – Can anything else revolutionize the market?
Related Content
Lucentis approved in China
Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched …
Pfizer extends portfolio with Brazilian generics deal
Pfizer is partnering with leading Brazilian generics firm Laboratorio Teuto Brasileiro to develop and commercialise …
Wellcome Trust signs £45m Indian collaboration
UK medical research charity the Wellcome Trust and the Indian government are to jointly develop …
